Atsena Therapeutics is a technology company.
Atsena Therapeutics has raised $205.0M across 2 funding rounds.
Atsena Therapeutics has raised $205.0M in total across 2 funding rounds.
Atsena Therapeutics has raised $205.0M in total across 2 funding rounds.
Atsena Therapeutics's investors include Abingworth, Morgenthaler Ventures, Sofinnova Investments, Canaan Partners, Vensana Capital.
Atsena Therapeutics is a clinical-stage gene therapy company founded in 2020 and headquartered in Durham, North Carolina, focused on developing treatments to reverse or prevent blindness caused by inherited retinal diseases (IRDs).[1][2][3] The company builds gene therapies using proprietary adeno-associated virus (AAV) technology, including novel spreading capsids like AAV.SPR, targeting patients with rare genetic vision disorders such as X-linked retinoschisis (XLRS) and Leber congenital amaurosis 1 (LCA1).[1][3][4] Its lead product, ATSN-201, addresses XLRS—a condition affecting retinal layers in males—through the ongoing Phase I/II LIGHTHOUSE trial, while ATSN-101 advances for LCA1 via a partnership with Nippon Shinyaku.[1][3][4] Atsena serves patients with IRDs, solving the problem of progressive vision loss where few effective therapies exist, evidenced by FDA designations like Fast Track, Orphan Drug, and Rare Pediatric Disease for its candidates.[1][3] Growth momentum is strong, highlighted by an oversubscribed $150 million Series C round in April 2025 to fund clinical advancement and preclinical programs.[1][3][4]
Atsena Therapeutics emerged from pioneering research in ocular gene therapy at the University of Florida, where co-founder and Chief Scientific Officer Shannon Boye, PhD, developed key technologies in her lab, including therapies for USH1B and others licensed to the company.[3][4] Founded in 2020 by experts in the field, Atsena was established to translate this academic innovation into clinical solutions for IRDs leading to blindness.[1][3] Early traction came from building a pipeline powered by novel AAV vectors tailored for retinal challenges, with pivotal moments including the completion of a Phase I/II trial for ATSN-101 showing clinical benefits across age groups and disease stages by late 2024.[3][4] The company gained further momentum through a November 2024 licensing deal with Nippon Shinyaku for ATSN-101's global pivotal trial and FDA recognitions, culminating in the 2025 Series C financing.[1][3][4]
Atsena rides the wave of advancing gene therapy for rare genetic diseases, particularly in ophthalmology, where precise retinal delivery remains a technical challenge amid growing demand for curative treatments over symptom management.[1][2][3] Timing is ideal post-2024 regulatory successes and funding surge, aligning with market forces like FDA's accelerated pathways (e.g., Fast Track for ATSN-201 in March 2025) and investor enthusiasm for IRD therapies affecting thousands, such as ~30,000 XLRS patients in the U.S. and EU.[1][3] The company influences the ecosystem by licensing tech from academia (e.g., University of Florida), partnering globally (Nippon Shinyaku), and advancing preclinical programs, potentially setting standards for non-surgical AAV delivery in vision restoration.[3][4]
Atsena is poised for key milestones, including updated LIGHTHOUSE data later in 2025, ATSN-101's global pivotal trial initiation, and progression of ATSN-201 toward approval, bolstered by its recent $150 million raise.[1][3][4] Trends like refined AAV capsids, expanded FDA incentives for rare diseases, and rising M&A in gene therapy will shape its path, potentially expanding to more IRDs like USH1B. Its influence may grow through commercialization successes, validating proprietary tech and inspiring retinal-focused biotechs, ultimately transforming outcomes for blindness prevention as promised in its clinical-stage momentum.[1][3]
Atsena Therapeutics has raised $205.0M across 2 funding rounds. Most recently, it raised $150.0M Series C in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $150.0M Series C | Abingworth, Morgenthaler Ventures, Sofinnova Investments | |
| Dec 1, 2020 | $55.0M Series A | Abingworth, Canaan Partners, Morgenthaler Ventures, Sofinnova Investments, Vensana Capital |